PATENT CLAIM ANALYSIS

Application Number: 16364023
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "293000"]

Abstract:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

Claim (Index 4):
The method of  claim 1 , wherein up to 65.625 mg of imiquimod is applied weekly.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 99.0
- Lexical Diversity: 1.78049
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14796296', '14091965', '15990590', '13559473', '13179315']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8835583364649415
- 35 USC 102 Novelty (BERT): 0.722939922951112
- Combined Prediction Score: 0.8674964951135586
- Mean Citation Score: 656.7854120000002
- Max Citation Score: 715.7073
- Similarity Product: 710.4864196161211

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test